Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UKK-0018 in Peanut Allergic Individuals
NCT07349212Phase 2Recruiting
- Sponsor
- Ukko
- Start
- Feb 2026
- Primary completion
- Mar 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, mRNA Therapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of UKK-0018 in peanut allergy, sponsored by Ukko. Started Feb 2026; status: recruiting.
02
Drugs
UKK-0018
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT07349212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07349212.